The financing round was led by aMoon and will support clinical trials and research pipelines.
"Since the inception of MiNA Therapeutics, we have been focused on advancing the Company by validating our innovative therapeutic approach in patients and establishing strategic collaborations with leading academic institutions and industry partners,"
Key Capital Partners has taken a minority stake in the educational virtual reality business.
"The team at Avantis has done a fantastic job in creating a product which adds real value in the classroom. Our research confirmed the huge potential for the business to grow rapidly over the next few years and I look forward to working with Nik and the team to turn this into reality."